Zehra Kaya

Zehra Kaya

Auto-generated profile, based on publicly available information

Zehra Kaya

Department of Medical Biology, Faculty of Medicine, Van Yuzuncu Yil University, Van, Turkey

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 March 2013 in Journal of Pineal Research
Verified
Journal Article
Closed access
PDF file
AŞAhmet Özer Şehirli
Ahmet Özer Şehirli
DKDerya Koyun
Derya Koyun
ŞTŞermin Tetik
Şermin Tetik
DÖDerya Özsavcı
Derya Özsavcı
ÖYÖmer Yiğiner
Ömer Yiğiner
GSGöksel Sener
Göksel Sener

23 November 2015 in Journal of Endocrinological Investigation
Verified
Journal Article
Closed access
PDF file
ZKZ. Kaya
Z. Kaya
SCS. Caglayan
S. Caglayan
MAMustafa Akkiprik
Mustafa Akkiprik
CAC. Aral
C. Aral
GOG. Ozisik
G. Ozisik
AOA. Ozer
A. Ozer

28 November 2014 in Asian Pacific Journal of Cancer Prevention
Verified
Journal Article
Open access
PDF file
EDEbubekir Dirican
Ebubekir Dirican
ZKZehra Kaya
Zehra Kaya
GAGokce Gullu Amuran
Gokce Gullu Amuran
IPIrem Peker
Irem Peker
TOTolga Ozmen
Tolga Ozmen
MAMustafa Akkiprik
Mustafa Akkiprik
Detection of PIK3CA Gene Mutations with HRM Analysis and Association with IGFBP-5 Expression Levels in Breast Cancer PIK3CA;PI3K;IGFBP5;HRM assay;Turkish breast cancer;mutation; Breast cancer is the second most common cancer and second leading cause of cancer deaths in women. Phosphatidylinositol-3-kinase (PI3K)/AKT pathway mutations are associated with cancer and phosphatidylinositol-4, 5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA) gene mutations have been observed in 25-45% of breast cancer samples. Insulin growth factor binding protein-5 (IGFBP-5) can show different effects on apoptosis, cell motility and survival in breast cancer. We here aimed to determine the association between PIK3CA gene mutations and IGFBP-5 expressions for the first time in breast cancer patients. Frozen tumor samples from 101 Turkish breast cancer patients were analyzed with high resolution melting (HRM) for PIK3CA mutations (exon 9 and exon 20) and 37 HRM positive tumor samples were analyzed by DNA sequencing, mutations being found in 31. PIK3CA exon 9 mutations (Q546R, E542Q, E545K, E542K and E545D) were found in 10 tumor samples, exon 20 mutations (H1047L, H1047R, T1025T and G1049R) in 21, where only 1 tumor sample had two exon 20 mutations (T1025T and H1047R). Moreover, we detected one sample with both exon 9 (E542Q) and exon 20 (H1047R) mutations. 35% of the tumor samples with high IGFBP-5 mRNA expression and 29.4% of the tumor samples with low IGFBP-5 mRNA expression had PIK3CA mutations (p=0.9924). This is the first study of PIK3CA mutation screening results in Turkish breast cancer population using HRM analysis. This approach appears to be a very effective and reliable screening method for the PIK3CA exon 9 and 20 mutation detection. Further analysis with a greater number of samples is needed to clarify association between PIK3CA gene mutations and IGFBP-5 mRNA expression, and also clinical outcome in breast cancer patients.

7 November 2021 in Molecular Biology Reports
Verified
Journal Article
Closed access
PDF file
ZKZehra Kaya
Zehra Kaya
BKBurak Mugdat Karan
Burak Mugdat Karan
NANecat Almalı
Necat Almalı

2 December 2016 in Breast Disease
Verified
Journal Article
Closed access
PDF file
SKSevgi Karabulut
Sevgi Karabulut
ZKZehra Kaya
Zehra Kaya
GAGokce Gullu Amuran
Gokce Gullu Amuran
IPIrem Peker
Irem Peker
TÖTolga Özmen
Tolga Özmen
MAMustafa Akkiprik
Mustafa Akkiprik
BACKGROUND: The insulin-like growth factor binding protein5 (IGFBP5) is often dysregulated in human cancers and considered neither a tumor suppressor nor an oncogene. OBJECTIVE: We aim to examine the reason of the changeable gene regulation of IGFBP5

7 September 2018 in Anticancer Research
Verified
Journal Article
Closed access
PDF file
YTYasin TÜLÜCE
Yasin TÜLÜCE
GGGokhan Gorgisen
Gokhan Gorgisen
IGIsmail Musab Gulacar
Ismail Musab Gulacar
IKIsmail Koyuncu
Ismail Koyuncu
MDMustafa DURGUN
Mustafa DURGUN
ZKZehra Kaya
Zehra Kaya
Background/Aim: Chemotherapeutic treatment options are often ineffective due to the development of resistance in cancer cells. Therefore, developing new anti-cancer agents is crucial for cancer treatment. Some triazine derivatives, their complexes and Copper(II) have anti-cancer effects on cancer cells. In this study, we aimed to determine the anti-proliferative effect of the novel synthesized Cu(II) complex with 3-(3-(4-fluorophenyl)triaz-1-en-1-yl) benzene-sulfonamide compound on the common cancer cell lines HeLa, MDA-MB-231, A2780 and MCF7. Materials and Methods: Common cancers cell lines were treated with copper complexes. Cell viability and apoptotic gene expression were examined. Results: Novel synthesized copper complex led to decreased viability of all cell lines. It also induced apoptosis via increasing the expression of caspase-3, caspase-9, Bax and p53 proteins and decreasing ERK expression. Conclusion: The novel synthesized copper complex has a significant inhibitory effect on the viability of cancer cell lines and can be considered as an antitumor agent for further studies.